Objectives: Plasmodium falciparum and Plasmodium vivax occur in Mauritania. Drug-resistant P. falciparum has been reported, but the drug-resistance status of P. vivax is unknown. The aims of the present study were to determine the prevalence of mutant pvdhfr, pvdhps and pvmdr1 genes and of pvmdr1 gene amplification in P. vivax isolates in Nouakchott, the capital city of Mauritania, and to establish a baseline for molecular surveillance of drug-resistant P. vivax in the country.
Introduction
Plasmodium vivax, the causative agent of relapsing benign tertian malaria, remains the second most common cause of malaria in the world with more than 80 million clinical cases annually. It is the most widely distributed human malaria parasite. It occurs in Central and South America, Asia, the Middle East and parts of Africa. 1 Unlike Plasmodium falciparum, P. vivax rarely causes mortality, but it is responsible for considerable morbidity and economic loss in endemic countries. 2 -4 Mauritania (latitude 15 -278N, longitude 5-178W) is situated in West Africa and is predominantly a Saharan country, with the northern two-thirds of its surface area occupied by the Sahara desert and the other third in the sub-Saharan south. The annual rainfall is low and increases from north to south. There is only one rainy season, from July to September. Malaria transmission, predominantly P. falciparum and, to a lesser extent, P. vivax, occurs in the southern one-third of the country bordering Senegal, Mali and the Atlantic coast.
vivo and in vitro, from Mauritania. 7 -9 Due to the lack of reliable health information as well as insufficient resources to confirm presumptive clinical diagnosis of malaria with laboratory examinations, the epidemiology of malaria in general, and in particular for P. vivax, is not well known in the country.
The presence of P. vivax in Mauritania was first reported in 1948. 10 In a later study conducted in 1996, infections in 28 of 77 patients (36%) with malaria, confirmed by microscopic examination of blood smears, were due to P. vivax, suggesting autochthonous P. vivax transmission in some patients who had never travelled outside Nouakchott. 11 More recently, Mint Lekweiry et al. 12 have shown a high proportion of P. vivax malaria (73.8%, of which 3.3% were mixed P. vivax/Plasmodium ovale), followed by P. ovale (24.6%) and P. falciparum (1.6%), by microscopic examination of blood smears and PCR, among 61 febrile patients in Nouakchott. At least two of the P. vivax-infected patients had never travelled outside Nouakchott and were considered to be autochthonous cases. The presence of P. vivax reported in these three studies, conducted in local populations, has further been confirmed by reports on imported P. vivax malaria originating from within Mauritania. 13 -15 The official national statistics suggest an increasing prevalence of malaria in Mauritania over the past two decades, of which 90% were due to P. falciparum. 16 The environmental factors that probably explain this increasing prevalence of P. falciparum malaria include the development of hydro-agricultural projects in the south as well as at oases in the north. The extent of malaria imported from neighbouring countries is unknown. Furthermore, the emergence and spread of antimalarial drug resistance is becoming an important factor. 5, 7, 9 As for P. vivax, the status of drug resistance is currently unknown in Mauritania.
Several mutations in drug resistance markers have been identified in P. vivax. Most of these genes had initially been identified and analysed in P. falciparum, and orthologous genes have been determined in P. vivax. Resistance to antifolates (pyrimethamine and sulfadoxine) is associated with specific point mutations in genes encoding dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in both P. falciparum and P. vivax, and an increasing number of specific mutations results in higher levels of resistance. 17 -21 Chloroquine resistance is associated with mutations in the gene encoding the P. falciparum chloroquine-resistance transporter (pfcrt), but mutations in the corresponding P. vivax chloroquine-resistance transporter orthologue (pvcrt-o) are not associated with chloroquine resistance. 22, 23 The P. falciparum multidrug-resistance gene 1 (pfmdr1) encodes a transmembrane transporter and has been associated with chloroquine, amino-alcohol and artemisinin resistance (pfmdr1 mutations) and mefloquine (also an amino-alcohol) resistance (pfmdr1 gene amplification). 24 Mutations in the orthologous gene, pvmdr1, have been reported to be associated with chloroquine resistance, while gene amplification may confer resistance to amodiaquine, mefloquine and artesunate. 25, 26 However, a role of pvmdr1 in conferring drug resistance is still not clear. 22,27 -30 Based on the currently available data on drug resistance markers in P. vivax, the objectives of the present study were to determine the prevalence of mutant pvdhfr, pvdhps and pvmdr1 genes and pvmdr1 gene amplification in isolates obtained from symptomatic patients residing in Nouakchott, and to establish a baseline for molecular surveillance of drug-resistant P. vivax in the country. The chloroquine-resistance marker pvcrt-o was not included in this study because its association with a resistant phenotype is not clearly established.
Methods

Study area
The study was conducted in Nouakchott (18805 ′ 2 ′′ N; 15858 ′ 42 ′′ W), the capital city of Mauritania (Figure 1 ). The city is situated in the Saharan zone, and the centre of the town is 4 miles from the Atlantic coast. The vegetation consists of orchards with diverse crops (date palm, vegetables, mint and alfalfa). The climate is Saharan with dry and wet seasons. The rainy season is short, extending from July to September with an average annual rainfall of 50-80 mm. The dry season is relatively cool (19-248C) between November and March, and relatively hot (26-308C) from April to June. The monthly average temperature ranges from 20.78C (in January) to 33.38C (in September), and the mean relative humidity varies from 33.4% to 79.1%. The current population in Nouakchott is estimated to be 661000. The city has four hospitals and nine health centres.
Patients and sample collection
All febrile patients attending the National Hospital and Chiekh Zayed Hospital between 2007 and 2009 were screened for malaria. After written informed consent had been obtained from at least one parent or legal guardian for febrile children and adolescents, and/or from febrile adolescents and adults, venous blood was collected in a EDTAcoated tube by venipuncture for microscopic examination of blood smear and a rapid diagnostic test (OptiMAL; DiaMed GmbH, Cressier, Switzerland). A blood sample was spotted onto Whatman 3MM filter paper, dried and stored at room temperature until use. The remainder of the sample was centrifuged, and the plasma and red cell pellets were stored separately at 2208C. Artemether/lumefantrine fixedcombination was prescribed to patients with a positive rapid diagnostic test, in accordance with the national antimalarial drug policy of the country. The patients were not followed up. This study was reviewed and approved by the Mauritanian National Ethics Committee. 
PCR
Parasite (and human) DNA was extracted from filter papers according to the modified protocol described by Kain and Lanar. 31 Briefly, a 2 mm diameter disc was punched out from the filter paper and placed in a 0.2 mL microtube, and 65 mL of TE buffer (10 mM Tris, 1 mM EDTA, pH 8) was added. The samples were incubated at 508C for 15 min, followed by 908C for 15 min to elute DNA.
Specific synthetic oligonucleotides were designed from the nucleotide sequences of the P. vivax ARI/Pakistan isolate for pvdhfr (GenBank accession no X98123), 32 Brazilian clinical isolate for pvdhps (accession no AY186730) 33 and the Sal-1 strain for pvmdr1 (accession no AY618622) 25 ( Table 1 ). The reaction mixture for the primary PCR amplification consisted of 3 mL of DNA template, 0.5 mmol of the forward and reverse primers, 0.2 mM deoxynucleoside triphosphate mixture (dGTP, dATP, dTTP and dCTP), 2.5 mM MgCl 2 , 1×PCR reaction buffer (Eurogentec, Angers, France) and 0.03 U/mL Taq DNA polymerase (Eurogentec) in a final volume of 20 mL. PCR was performed using a thermal cycler (Biometra, Gö ttingen, Germany) with the following programme for the three genes: denaturation at 948C for 5 min, annealing at 538C for 1 min and extension at 728C for 1 min, for a total of 45 cycles, followed by a final extension at 728C for 10 min. The secondary nested PCR was performed with a similar PCR mixture as for the primary amplification but using 2 mL of the primary PCR product. The same thermal cycling programme was used for secondary amplification (except that the annealing temperature was 658C). The amplified nested PCR products were visualized by agarose gel electrophoresis and ultraviolet transillumination. The expected band sizes for pvdhfr, pvdhps and pvmdr1 were 632, 767 and 547 bp, respectively.
Sequencing
For the sequencing reactions, the secondary amplified product (2 mL) was marked with fluorescent nucleotides in the following mixture: 3.2 pmol of nested PCR primers (Table 1 ), 2 mL of BigDye buffer and 2 mL of BigDye v1.1 (Applied Biosystems, Foster City, CA, USA) in a final volume of 20 mL. The thermal cycler was programmed as follows: 968C for 10 s, 508C for 5 s and 608C for 4 min for 25 cycles. Residual dye terminators (BigDye terminator V3.1) were removed by the BigDye Xterminator purification kit according to the manufacturer's instructions. An ABI Prism 3100 automated DNA sequencer (Applied Biosystems) was used to sequence the extension product. Sequences were analysed by using the BioEdit sequence alignment editor software version 7.0.9.0.
Quantification of pvmdr1 copy numbers by TaqMan real-time PCR
TaqMan real-time PCR (7900HT FastReal-Time PCR system; Applied Biosystems) was used to estimate pvmdr1 (PVX_080100) copy numbers relative to the single-copy gene pvaldolase (PVX_118255). The oligonucleotide primers and probes (Eurogentec, Seraing, Belgium) were designed by using Primer Express software (version 2.0) ( Table 1) . Individual PCRs were performed using TaqManUniversal PCR Master Mix (Applied Biosystems), 900 nM forward primer, 900 nM reverse primer, 200 nM TaqMan and 5 mL of template DNA in a final volume of 25 mL. The reaction mixtures were prepared at 48C in a 96-well optical reaction plate (Applied Biosystems) covered with optical adhesive covers. The thermal cycling conditions were 508C for 2 min, 958C for 10 min, and 50 cycles of 958C for 15 s and 608C for 1 min. Each sample was assayed in triplicate and analysed with Drug-resistant Plasmodium vivax in Mauritania SDS software (version 2.2.1; Applied Biosystems). The PCR efficiencies of all primer pairs were evaluated using a series of dilutions of P. vivax genomic DNA and were found to be sufficiently close to obviate the need for any correction factor. Therefore, the 2 2DDCt method (where Ct indicates the threshold cycle) for relative quantification was used, adapted to estimate the number of copies of pvmdr1 with the formula DDCt ¼(Ct pvmdr1 2 Ct pvaldolase ) sample 2(Ct pvmdr1 2Ct pvaldolase ) calibrator . 34, 35 Genomic DNA extracted from P. vivax was used for calibration, and pvaldolase served as the control gene in all experiments.
Data interpretation
The key codons associated with pyrimethamine resistance in P. vivax were determined by Eldin de Pécoulas et al. 32, 36 The complete panel of combinations of pvdhfr mutations reported so far from different endemic regions has been reviewed by Hawkins et al. 37 In the present study, the wild-type pvdhfr genotype was defined as residues I13-P33-F57-S58-T61-S117-I173, while the mutant pvdhfr genotype was defined as at least one amino acid change in the corresponding residues, 13L-33L-57L/I-58R-61M-117N/T-173L/F.
The key pfdhps codon mutations that are associated with sulfadoxine resistance (S436A/F, A437G, K540E, A581G and A613S) correspond to S382A/C, A383G, K512M/T/E, A553G/C and V585, respectively, in pvdhps. 33 So far, only V585 has been observed. The wild-type codon at position 585 is still undetermined. In the present paper, the wild-type pvdhps genotype is defined as S382-A383-K512-A553-V585, and mutant genotype is defined as at least one of the following residues: 382A/C-383G-512M/T/E-553G/C and any amino acid residue other than Val in position 585.
In P. falciparum, mutations in the following pfmdr1 codons have been associated with drug resistance: N86, Y184, S1034, N1042 and D1246. Amino acid changes in the corresponding positions in pvmdr1 (N91, Y189, S1071, N1079 and D1291) are not associated with a chloroquine-resistant phenotype. 25, 38 The amino acid substitutions Y976F and F1076L have been suggested to be the key changes that may be associated with chloroquine resistance in P. vivax. 25 Field studies conducted in Brazil, Papua New Guinea, Thailand and Madagascar have confirmed the presence of these two mutations. 22, 27, 28, 38, 39 The pvmdr1 genotypes were therefore defined as wild-type (Y976-F1076) and mutant (976F-1076L). The presence of mixed alleles was deduced when a double peak was observed in the electropherogram.
Since pfmdr1 (also probably pvmdr1) gene amplification is correlated with both mefloquine and lumefantrine resistance, and artemether/ lumefantrine is one of the current artemisinin-based combination therapies (ACTs) employed in Mauritania, pvmdr1 copy number was determined. One copy was considered as an indicator of susceptibility to amino-alcohols, while two or more pvmdr1 gene copies suggested drug resistance.
Results
Of a total of 439 febrile patients screened for malaria, 110 were P. vivax positive by microscopy and/or rapid diagnostic test, 1 patient had mixed P. falciparum and P. vivax, and none had Plasmodium malariae, P. ovale or pure P. falciparum. All 110 pure P. vivax samples, as well as the one P. falciparum/P. vivax co-infection, yielded the expected band sizes by PCR. Sequences showed evidence for mixed pvdhfr alleles in three P. vivax isolates. pvdhfr, pvdhps and pvmdr1 sequence data were available from 78% (86/110), 85% (94/110) and 94% (103/110) of the samples, respectively. At least one of the molecular markers was successfully amplified and sequenced for each P. vivax isolate.
pvdhfr was successfully amplified and sequenced from 86 isolates. The majority of the isolates [76 of 86 (88%)] were characterized by the wild-type pvdhfr genotype IPFSTSI (codons 13, 33, 57, 58, 61, 117, 173) ( Table 2 ). The remaining 10 isolates (12%) carried the double mutation S58R and S117N, either as pure alleles (n¼ 7) or mixed alleles (n¼ 3). The mutant genotypes of these 10 isolates were IPFRTNI for the pure alleles and IPFS/ RTS/NI for mixed alleles (mutated codons shown in bold face). Nine novel mutations were found. Five mutations were synonymous (A45G, T114C, T207C, C360T and C493T in the nucleotide sequence) and four mutations were non-synonymous: G190A, G229C, A361T and C510A in the nucleotide sequence, corresponding to V64M, E77Q, I121F and C170stop in the amino acid sequence, respectively. As reported in earlier studies, 32,36 a 4 amino acid repeat unit, GGDN, was observed between residues 88 and 106. Three amino acid repeats were found in all isolates.
pvdhps sequence data were available from 94 isolates. All were characterized by the wild-type genotype SAKAV (codons 382, 383, 512, 553, 585). Five novel mutations were found in five different isolates at positions 388, 400, 455, 505 and 550 (C1163T, C1199T, A1363G, G1513A and T1649C in the nucleotide sequence, corresponding to P388L, P400L, T455A, G505R and L550P in the amino acid sequence, respectively).
pvmdr1 was successfully amplified from 103 isolates. Of these isolates, 75 (73%) had the wild-type Y976, and 28 (27%) carried Mint Lekweiry et al.
the mutation Y976F. Two isolates (2%) had the wild-type F1076, and 101 (98%) carried the mutation F1076L, while 28 (27%) harboured the double mutation. Two novel mutations were observed, a synonymous change (C3064T; 1022 in the amino acid sequence) and a non-synonymous change at the position 958 (C2873T, corresponding to T958M). The copy numbers of the pvmdr1 gene were successfully evaluated in 105 isolates. Of these isolates, 102 (97%) had one copy of pvmdr1 and three had two copies (Table 2) . Of these three isolates, two had the double mutant genotype F976-L1076, and the other had the single mutant genotype Y976-L1076. The genotypes of individual isolates or groups of isolates are presented in Table 3 .
Discussion
Until 2005, uncomplicated malaria (P. falciparum and P. vivax) had been treated with chloroquine as the first-line and sulfadoxine/pyrimethamine as the second-line drug in Mauritania. A large majority of patients had been treated on the basis of presumptive diagnosis. For malaria prevention in pregnant women, chloroquine had been prescribed for weekly intake. Since 2006, artesunate/amodiaquine and artemether/lumefantrine have been introduced in the country for the first-line treatment of P. falciparum malaria. 40 Sulfadoxine/pyrimethamine is employed for intermittent preventive treatment in pregnant women. Due to the scarcity of P. vivax infections, there is currently no defined national policy on the treatment of P. vivax infections in Mauritania. Quinine is still reserved for the treatment of severe malaria. These antimalarial treatment policies have not been based on clinical studies on therapeutic efficacy. In fact, between 1996 and 2010 only two studies have been performed in Mauritania, both in 1998 on chloroquine efficacy. 41, 42 The results of the present study confirm the occurrence of P. vivax transmission in Nouakchott. In an earlier study conducted with 416 febrile patients in 1996 in Nouakchott, 11   Table 3 . Non-synonymous polymorphisms observed in different groups of P. vivax isolates Nucleotide polymorphisms (amino acid changes) pvdhfr pvmdr1 pvmdr1 copy no.
No. of isolates
NA, not available. For pvdhfr, all isolates exhibited the wild-type alleles, with residues I13, P21, P33, C49, F57, T61, S93, N130 and I173, and three GGDN repeats at position 88-106. All samples presented a wild-type pvdhps genotype. Bold characters denote mutations. Novel non-synonymous mutations include V64M, E77Q and I121F in pvdhfr; P388L, P400L, T455A, G505R and L550P in pvdhps in five different isolates; and T958M in pvmdr1.
Drug-resistant Plasmodium vivax in Mauritania 371 JAC 61.0% (47/77) of malaria-positive cases were due to P. falciparum, 36.4% (28/77) were due to P. vivax, 1.3% (1/77) were due to P. ovale and 1.3% (1/77) were due to P. malariae. In the present study, the relative proportion of P. falciparum (0.9%) and P. vivax (100%, including one P. falciparum/P. vivax mixed infection) showed a large predominance of P. vivax. The underlying causes of this inversion of P. falciparum/P. vivax ratio are currently unknown. Nonetheless, if the current trend continues, a more affordable and appropriate therapeutic strategy may be required. Despite the presence of Anopheles spp. in this urban site, no specific entomological data are available. Further surveys are currently being undertaken to characterize the epidemiology of P. vivax malaria in Nouakchott.
The results of the present study also suggest that, compared with many other countries where P. vivax is endemic, the prevalence of mutant dhfr alleles associated with pyrimethamine resistance is low in Mauritania. P. vivax malaria that is clinically resistant to standard drugs, such as chloroquine, sulfadoxine/ pyrimethamine, mefloquine and primaquine, is known to be present in certain foci, mostly in Asia and parts of South America where P. falciparum and P. vivax co-exist and the latter has been exposed to antifolate drugs. 37 Molecular assays conducted in areas where P. falciparum and P. vivax transmission is moderate (French Guiana, Brazil, Vanuatu, Papua New Guinea, Indonesia, East Timor, Philippines, China, Vietnam, Thailand, India, Sri Lanka and Madagascar) have shown a high prevalence of mutant pvdhfr, mostly F57L/I, S58R and S117N/T, and a few cases of I173L/F. 43 -51 Similarly, pvdhps mutations at positions 382, 383, 512 and 553 (but not at position 585) have been reported from these countries. By contrast, in Iran and Afghanistan, where malaria transmission occurs seasonally at a relatively low level and where P. vivax largely predominates over P. falciparum, the prevalence of mutant pvdhfr was low: mutant R58 in 17.5% and 4%, and mutant N117 in 26% and 12% of isolates in Iran and Afghanistan, respectively. 52, 53 Furthermore, in these two countries, only a single isolate [1 of 171 Afghan isolates (0.6%) and none of 189 Iranian isolates] carried the mutation A383G in pvdhps, and all isolates carried the wild-type A553. Likewise, in Korea, where P. vivax is a re-emerging parasite, single N117 or T117 dhfr mutants (14%) and double mutants involving codons 57, 58, 117 or 173 occur at a low prevalence. 54 Further phenotypic studies (in vitro and clinical responses) are required to determine whether these genotype variations reflect drug susceptibility or geographic variation independent of drug susceptibility.
The pvdhfr and pvdhps genotypes of Mauritanian isolates collected in Nouakchott were 88% and 100% wild-type, respectively. Moreover, pvdhfr mutations involved only two (amino acids 58 and 117) of the seven alleles that have been reported to be associated with antifolate resistance. Therefore, the current P. vivax drug-resistant status in Nouakchott is characterized by a high proportion of drug-susceptible molecular profiles.
pvmdr1 mutations have been suggested to be associated with chloroquine resistance. The double mutations Y976F and F1076L have been observed in P. vivax isolates from Thailand and Indonesia. 25 Parasites from Thailand, Indonesia and Papua New Guinea carrying Y976F are characterized by reduced chloroquine susceptibility in vitro. 26, 39 Several studies suggest that F1076L may not be an indicator of drug resistance, but rather a geographic variant since this mutation was observed in close to 100% of isolates from Madagascar, the Republic of Korea and Mauritania, about 30% in isolates from Thailand and Indonesia, and fewer (14%) in Brazil. 22, 25, 27, 55 Chloroquine-or amodiaquine-treatment failure may be associated with P. vivax isolates carrying the Y976F substitution. 22, 28 However, other studies did not confirm an association between pvmdr1 mutations and drug resistance. 29, 30 Unfortunately, in the present study in vitro and clinical responses of P. vivax isolates were not assessed, and the practical significance of mutant Mauritanian P. vivax isolates for treatment cannot be determined.
pvmdr1 gene amplification has been suggested to be associated with amodiaquine, artesunate and mefloquine resistance in Thailand, in particular in areas where mefloquine has been employed intensively for over two decades. 26, 38, 39, 55 When pvmdr1 amplification occurs, it is usually a duplication (i.e. 2 gene copies). Amplification with 3 copies (none are reported .3) has been observed in only a few isolates. Our finding is in agreement with previous studies. 26, 38, 39, 55 A large majority of Mauritanian isolates had a single pvmdr1 gene copy, and only 3 of 105 isolates had two copies. Interestingly, these isolates with pvmdr1 amplification also carried mutations in residue 976 or 1076, or both. Further studies including in vitro assays and/or clinical response are required to determine the phenotype of such isolates in Mauritania.
The origin of P. vivax in Mauritania is not known. It may have been introduced from known P. vivax foci of oasis malaria in Algeria and Morocco through nomadic migration of some tribes, imported through human migration from neighbouring countries (Mali), or the Cape Verde islands, or by European travellers or explorers during the colonial period. The ethnic origin of the Moor people (mostly Duffy-positive blood group) favours P. vivax susceptibility although several reports have demonstrated the possibility of P. vivax infection in Duffy-negative individuals. 56 At present, there is no scientific evidence that supports any of the possible hypotheses on the origin of P. vivax in Nouakchott. To explain the apparent homogeneity of P. vivax isolates observed in the present study, further studies on the population genetics of the parasites, human hosts and mosquitoes are required. Moreover, the diversity of pvdhfr, pvdhps and pvmdr1 sequences, including novel mutations, may offer a complementary means to determine the origin of Mauritanian P. vivax populations.
The present study is the first report based on molecular epidemiology on the status of drug-resistant P. vivax in West Africa, and the second report on drug-resistant P. vivax in the African continent, following one from Ethiopia in East Africa. 57 Drug-resistant P. vivax has not been reported elsewhere from the African continent, probably due to under-reporting, incomplete data or the absence of drug resistance. Furthermore, P. vivax is relatively uncommon in Africa, except in east Africa, and is limited to foci in northern Africa, and some islands (Cape Verde, Sã o Tome y Príncipe and islands belonging to Equatorial Guinea). In Madagascar all four human malaria species co-exist, and drug-resistant P. falciparum and P. vivax have been reported. 58 Data on the molecular markers of drug resistance in Mauritanian P. vivax isolates in the present study will serve as a baseline for further monitoring of drug-resistant P. vivax in Nouakchott.
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